Bukwang Pharmaceutical Co., Ltd. (KRX:003000)

Bukwang Pharmaceutical Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	29,524	90,091	151,227	85,517	82,777	79,291
Short-Term Investments	188,027	40,000	-	-	1,500	10,300
Cash & Short-Term Investments	217,552	130,091	151,227	85,517	84,277	89,591
Cash Growth	85.00%	-13.98%	76.84%	1.47%	-5.93%	138.37%
Accounts Receivable	27,449	23,559	35,729	87,950	90,428	103,675
Other Receivables	1,657	994.31	1,647	360.04	2,413	309.45
Receivables	29,106	24,553	37,376	88,310	92,842	103,985
Inventory	52,781	41,667	56,832	38,607	39,294	51,375
Prepaid Expenses	306.8	398.29	166.97	173.46	205.7	216.08
Other Current Assets	6,170	7,030	8,576	6,134	3,476	3,043
Total Current Assets	305,915	203,739	254,179	218,741	220,095	248,209
Property, Plant & Equipment	143,271	141,481	122,789	123,960	124,531	106,298
Long-Term Investments	14,196	16,775	31,626	35,132	36,963	34,189
Goodwill	406.62	406.62	878.73	834.51	828.7	827.05
Other Intangible Assets	7,668	5,868	9,177	6,157	6,151	6,172
Long-Term Deferred Tax Assets	-	-	-	-	3.63	7.27
Other Long-Term Assets	1,536	4,910	10,368	16,105	8,843	5,266
Total Assets	472,993	373,180	429,017	400,929	397,417	400,969
Accounts Payable	9,340	5,062	2,368	16,530	7,421	10,157
Accrued Expenses	-	1,907	2,978	1,755	1,776	2,055
Short-Term Debt	30,000	-	-	-	-	20,000
Current Portion of Leases	324.04	130.19	217.6	242.91	444.17	407.98
Current Income Taxes Payable	7.04	-	357.47	4,312	3,996	7,291
Other Current Liabilities	26,776	28,299	91,622	21,764	23,358	21,293
Total Current Liabilities	66,447	35,398	97,544	44,603	36,995	61,204
Long-Term Debt	49,394	79,024	78,525	-	-	-
Long-Term Leases	544.38	269.91	644.17	687.88	1,114	1,139
Long-Term Deferred Tax Liabilities	15,351	13,917	10,068	11,011	11,217	4,984
Other Long-Term Liabilities	425.12	425.12	7,971	72,780	68,030	62,450
Total Liabilities	132,161	129,035	194,752	129,082	117,356	129,778
Common Stock	51,507	36,402	36,402	36,402	36,402	33,289
Additional Paid-In Capital	98,653	12,452	4,808	6,800	7,357	7,071
Retained Earnings	174,671	166,822	225,783	258,585	264,703	273,253
Treasury Stock	-	-	-50,784	-50,784	-50,784	-50,268
Comprehensive Income & Other	15,617	28,000	10,103	12,215	11,930	-4,846
Total Common Equity	340,448	243,676	226,311	263,217	269,608	258,499
Minority Interest	383.7	469.85	7,953	8,630	10,453	12,692
Shareholders' Equity	340,832	244,146	234,265	271,847	280,061	271,191
Total Liabilities & Equity	472,993	373,180	429,017	400,929	397,417	400,969
Total Debt	80,263	79,424	79,387	930.79	1,558	21,547
Net Cash (Debt)	137,289	50,667	71,840	84,586	82,719	68,044
Net Cash Growth	258.43%	-29.47%	-15.07%	2.26%	21.57%	91.64%
Net Cash Per Share	1846.89	740.15	1049.46	1235.65	1208.27	991.46
Filing Date Shares Outstanding	139.14	68.45	68.45	68.45	68.45	62.25
Total Common Shares Outstanding	139.14	68.45	68.45	68.45	68.45	68.48
Working Capital	239,468	168,341	156,634	174,138	183,101	187,005
Book Value Per Share	2446.75	3559.67	3306.00	3845.13	3938.48	3775.04
Tangible Book Value	332,373	237,401	216,255	256,226	262,628	251,500
Tangible Book Value Per Share	2388.72	3468.00	3159.10	3743.01	3836.52	3672.83
Land	112,939	113,314	92,875	92,875	92,875	71,163
Buildings	51,998	51,499	51,450	50,602	50,602	50,577
Machinery	51,880	49,276	48,406	48,080	46,343	46,030
Construction In Progress	330.6	311.17	-	76.21	-	52.2

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.